Has Loida Gonzalez Rodriguez received payments from drug or device companies?

Yes. Drug and device makers reported $7,746 in general payments to Loida Gonzalez Rodriguez across 339 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Loida Gonzalez Rodriguez did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Loida Gonzalez Rodriguez come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Loida Gonzalez Rodriguez

Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1164678736

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 339 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations.

$7,746in general payments, 2019–2025

Across 339 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$1K
Novo Nordisk$792
Sanofi-aventis U.S. LLC$638
Abbott$636
Eli Lilly Export S.A. Puerto Rico Branch$627
PBG Puerto Rico LLC$554
plus $3K from 16 others

$243,184in research payments, 2019–2025

Across 25 payments — averaging $9727.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly Export S.A. Puerto Rico Branch$169K
AbbVie$67K
Eli Lilly$7K

What the payments were for

Food & beverage$7,746100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	40	$1,038
Novo Nordisk	38	$792
Sanofi-aventis U.S. LLC	29	$638
Abbott	31	$636
Eli Lilly Export S.A. Puerto Rico Branch	25	$627
PBG Puerto Rico LLC	27	$554
Amgen	19	$483
AstraZeneca	24	$477
Dexcom, Inc.	24	$477
Merck	21	$449
Johnson & Johnson	15	$425
AbbVie	13	$266
Novartis	12	$262
Radius Health, Inc.	4	$175
Bayer Puerto Rico Inc.	7	$139
GSK	1	$90
Rhythm Pharmaceuticals, Inc.	2	$52
Pfizer Pharmaceuticals LLC	2	$47
Medtronic	2	$47
Boston Scientific	1	$29
Corcept Therapeutics	1	$23
Verity Pharmaceuticals Inc.	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,746 in reported general payments places this provider in the 70th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
SynthroidLevothyroxine Sodium	20	$1,148
Levothyroxine Sodium	24	$360
Hydrocortisone	18	$331
Atorvastatin Calcium	16	$186
Losartan Potassium	11	$159
Hydrochlorothiazide	14	$102
Gabapentin	11	$78
Amlodipine Besylate	12	$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieSynthroid	$266	$1,14820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in San Juan

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →